CN113788951A - Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof - Google Patents
Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof Download PDFInfo
- Publication number
- CN113788951A CN113788951A CN202111168338.4A CN202111168338A CN113788951A CN 113788951 A CN113788951 A CN 113788951A CN 202111168338 A CN202111168338 A CN 202111168338A CN 113788951 A CN113788951 A CN 113788951A
- Authority
- CN
- China
- Prior art keywords
- group
- polyamino acid
- polyethylene glycol
- side chain
- polyamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 title claims abstract description 164
- 108700021021 mRNA Vaccine Proteins 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 229940126582 mRNA vaccine Drugs 0.000 title abstract description 73
- 238000002716 delivery method Methods 0.000 title description 2
- 239000000693 micelle Substances 0.000 claims abstract description 66
- 229920001223 polyethylene glycol Polymers 0.000 claims description 85
- 239000002202 Polyethylene glycol Substances 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 125000005647 linker group Chemical group 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 229920001577 copolymer Polymers 0.000 claims description 19
- 229940024606 amino acid Drugs 0.000 claims description 18
- 125000000524 functional group Chemical group 0.000 claims description 18
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000012650 click reaction Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 229960002885 histidine Drugs 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 8
- 229960003121 arginine Drugs 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 229960002449 glycine Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 229960003136 leucine Drugs 0.000 claims description 7
- 229960005190 phenylalanine Drugs 0.000 claims description 7
- 229960004799 tryptophan Drugs 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 229960002743 glutamine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 229960002429 proline Drugs 0.000 claims description 6
- 229960001153 serine Drugs 0.000 claims description 6
- 229960004441 tyrosine Drugs 0.000 claims description 6
- 108010039918 Polylysine Proteins 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 125000003827 glycol group Chemical group 0.000 claims description 5
- 229920000656 polylysine Polymers 0.000 claims description 5
- 229960002898 threonine Drugs 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 108010041986 DNA Vaccines Proteins 0.000 claims description 3
- 229940021995 DNA vaccine Drugs 0.000 claims description 3
- 229940022005 RNA vaccine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 abstract description 50
- 238000000034 method Methods 0.000 abstract description 26
- 230000004044 response Effects 0.000 abstract description 11
- 210000000805 cytoplasm Anatomy 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 6
- 210000003712 lysosome Anatomy 0.000 abstract description 4
- 230000001868 lysosomic effect Effects 0.000 abstract description 4
- 238000003776 cleavage reaction Methods 0.000 abstract description 3
- 239000002539 nanocarrier Substances 0.000 abstract description 3
- 230000007017 scission Effects 0.000 abstract description 3
- 230000003204 osmotic effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 32
- -1 polyethylene Polymers 0.000 description 30
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 102000053602 DNA Human genes 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 229960002317 succinimide Drugs 0.000 description 20
- 239000000843 powder Substances 0.000 description 18
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 229960002685 biotin Drugs 0.000 description 15
- 239000011616 biotin Substances 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 239000007822 coupling agent Substances 0.000 description 15
- 125000003277 amino group Chemical group 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000008685 targeting Effects 0.000 description 14
- 230000002209 hydrophobic effect Effects 0.000 description 13
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000008176 lyophilized powder Substances 0.000 description 12
- 239000011259 mixed solution Substances 0.000 description 12
- 239000002105 nanoparticle Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229960005322 streptomycin Drugs 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 238000002296 dynamic light scattering Methods 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000002086 nanomaterial Substances 0.000 description 8
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 7
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 7
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 7
- 229920000271 Kevlar® Polymers 0.000 description 7
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000004761 kevlar Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- KZCOBXFFBQJQHH-UHFFFAOYSA-N octane-1-thiol Chemical compound CCCCCCCCS KZCOBXFFBQJQHH-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000711573 Coronaviridae Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 238000002356 laser light scattering Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 230000002132 lysosomal effect Effects 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 5
- 108091023045 Untranslated Region Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 125000004185 ester group Chemical group 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 230000033116 oxidation-reduction process Effects 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241000342557 H7N9 subtype Species 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000003172 aldehyde group Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000007824 aliphatic compounds Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000011218 binary composite Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- VTXVGVNLYGSIAR-UHFFFAOYSA-N decane-1-thiol Chemical compound CCCCCCCCCCS VTXVGVNLYGSIAR-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229940094933 n-dodecane Drugs 0.000 description 2
- 230000001293 nucleolytic effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229940089531 polyethylene glycol 3500 Drugs 0.000 description 2
- 229950006348 sarilumab Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- MLRVZFYXUZQSRU-UHFFFAOYSA-N 1-chlorohexane Chemical compound CCCCCCCl MLRVZFYXUZQSRU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- WHSOKGZCVSCOJM-UHFFFAOYSA-N 4-amino-1-benzylpyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1CC1=CC=CC=C1 WHSOKGZCVSCOJM-UHFFFAOYSA-N 0.000 description 1
- UINSGVKWAFJDPI-UHFFFAOYSA-N 6-[[4-(aminomethyl)phenyl]methoxy]-7h-purin-2-amine Chemical compound C1=CC(CN)=CC=C1COC1=NC(N)=NC2=C1NC=N2 UINSGVKWAFJDPI-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150007813 NIH gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 101001039735 Rattus norvegicus Mast cell protease 1 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 238000005598 Sharpless reaction Methods 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 229940027570 adenoviral vector vaccine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- NGDMLQSGYUCLDC-UHFFFAOYSA-N pyren-1-ylmethanol Chemical compound C1=C2C(CO)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 NGDMLQSGYUCLDC-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 108040000979 soluble NSF attachment protein activity proteins Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001347 α-poly-L-lysine Polymers 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 229920001351 ε-poly-L-lysine Polymers 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a polyamino acid for targeted delivery of an mRNA vaccine, a preparation method and application thereof. The side chain modified polyamino acid of the invention introduces disulfide bond cracked in reducing environment on the side chain, which can promote the response of micelle to reducing environment and low pH value in cytoplasm, and help mRNA vaccine actively escape from 'lysosome trap' and enter into cytoplasm. Active cleavage of the nanocarriers can release mRNA more efficiently than passive osmotic pressure dominated escape processes.
Description
Technical Field
The invention belongs to the field of polymer materials, and relates to a polyamino acid for mRNA vaccine targeted delivery, and a preparation method and application thereof.
Background
Viruses are a significant public health safety threat that endangers human health. The use of vaccines is an effective means for combating viruses in humans. Since the seed 'vaccinia' was used to overcome smallpox virus, vaccines have helped humans to effectively control and prevent a variety of viral diseases, including hepatitis a, hepatitis b, meningitis b, and influenza. The development of vaccines against the fatal Ebola (Ebola) virus and Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and 2019 coronavirus disease (COVID-19) caused by coronavirus is an urgent need to control the epidemic situation of virus infection. According to different technical routes, the types of vaccines include inactivated vaccines, recombinant protein vaccines, adenoviral vector vaccines, and nucleic acid vaccines. Wherein, ribonucleic acid (RNA) vaccine generates a protein segment of a binding region with a virus receptor, a virus capsid protein or other conserved regions in the cytoplasm of human cells as an antigen through a protein transcription-translation mechanism of the cells, induces an immune system to generate antibodies, and realizes the immunity to the virus.
Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are important genetic materials in life systems. According to the life center rule, genetic information is transcribed and translated into functional proteins through the process of DNA-RNA-protein. In this process, the cells use messenger rna (mrna) as a template to translate the protein. Messenger RNA (mrna) is a class of RNA molecules that stores genetic information in the base pair sequence of nucleotides a-U, G-C, transfers the genetic information from DNA to ribosomes, where it serves as a template for protein synthesis and expresses protein products. The mRNA vaccine does not need protein expression and purification, and mRNA is transferred to human cells to form immunity by synthesizing related sequence mRNA of the virus in vitro. mRNA vaccines thus have many advantages: 1) mRNA is easy to produce and purify in vitro, removes the complex process of preparing protein drugs and virus vectors, and can avoid host protein and virus-derived pollution; 2) the production process of the mRNA has strong universality, can be quickly applied to producing different target proteins, saves the time for developing the medicament and improves the efficiency; 3) mRNA can be translated into protein only by entering cytoplasm without entering cell nucleus, so that gene insertion and integration do not exist, and the safety of the medicine is improved; 4) the half-life can be altered by adjusting sequence modifications and delivery vectors. The mRNA vaccine has the characteristics of high biological safety, flexible design, rapid development and strong universality, so that the mRNA vaccine becomes an important way for vaccine development. The mRNA vaccine can not only prevent and inhibit the infection of the virus in organisms, but also treat tumors by using the mRNA vaccine, and for example, the mRNA vaccine developed aiming at melanoma and small cell lung cancer is reported to enter the clinical test stage.
In clinical trials, it has been found that the effectiveness of mRNA vaccines is limited by the following specific factors: 1) inability to pass freely through biological membranes; 2) are easily decomposed by RNA degrading enzymes (RNases) in plasma and tissues; 3) after entering the cell, the endosome is captured by endocytosomes (endosomes) and develops into "lysosomal traps" (lysosome trapping), which cannot function. Therefore mRNA immunization efficiency depends on improving the stability of mRNA vaccines in vivo and overcoming intracellular vesicle transport mechanisms. Due to the hydroxyl substitution at nucleotide position 2, RNA is less stable in physiological environments than DNA. To avoid hydrolytic and enzymatic consumption of RNA during circulation in the body, mRNA vaccines and drugs require encapsulation protection of the delivery system. However, the delivery efficiency of existing delivery systems is low due to the presence of "lysosomal traps," and efficient delivery of mRNA vaccines and drugs cannot be achieved.
In order to allow efficient entry of the vaccine into cells and release from "lysosomal traps" into the cytosol through a delivery system, the manner in which the mRNA vaccine is administered and the mode of delivery play a key role in the control of pharmacokinetics and dosage. The prior art uses liposomes, lipid nanoparticles as delivery systems to make nanocomposites of mRNA vaccines and drugs. Lipid nanoparticles containing positively charged lipid molecules can achieve good loading of negatively charged nucleic acid molecules by electrostatic interactions. In order to efficiently release mRNA vaccines and drugs from "lysosomal traps" into the cytosol, optimization of the stability, environmental response and targeted delivery of the delivery system is required. The environmental response includes changes in the microenvironment of the cells and tissues, such as pH, oxidation-reduction environment, and changes in hydrophilic-hydrophobic environment caused by contact with membrane structures. The target delivery capability refers to the capability of performing biological functionalization on a nucleic acid delivery system and obtaining target delivery capability on target cells (such as cancer cells, B cells and T cells of the immune system) and tissues (such as lymphoid tissues, lung, small intestine and other organs) by using biological functional ligands and antibodies.
Micelles are a form of nano aggregates formed spontaneously in an aqueous solution, are mostly spherical and also can be columnar. Surfactants containing both hydrophilic and lipophilic groups spontaneously associate into micelles when they reach and exceed a Critical Micelle Concentration (CMC) in solution. The micelle is in dynamic balance in the solution, can wrap and release the effective components, and is suitable for serving as a delivery system. The hydrophobic core of the micelle makes it possible to encapsulate poorly soluble hydrophobic compounds in the aqueous phase. The micelle having a negatively or positively charged component may be loaded with an active ingredient having a positive or negative charge. The micelle with biocompatibility can maintain the activity of the contacted biomolecules, ensure low cytotoxicity, and can be biodegraded in vivo or harmlessly discharged in vitro. The prior art reports the formation of high molecular micelles by structural design of block copolymers. For example under the trade name Pluronic®A class of polyethylene oxide-polypropylene oxide-polyethylene oxide (PEO-PPO-PEO) triblock polymeric materials of F-127. In addition, it has been reported that a graft dendrite copolymer having a chitin backbone forms a micellar nanomaterial.
Disclosure of Invention
In order to overcome the low delivery efficiency of existing nucleic acid molecules (such as mRNA vaccines) due to "lysosomal traps", the present invention aims to provide a polyamino acid micellar delivery system that is sensitive to oxidation-reduction environment and/or pH changes in cells and tissue structures. Specifically, the invention provides a polyamino acid for delivering nucleic acid molecules, and a preparation method and application thereof. Polyamino acids are a class of backbone types that are completely biodegradable, and the backbone of polyamino acids is more biologically stable in the in vivo environment than ester linkages based on amide linkages.
The purpose of the invention is realized by the following technical scheme:
a side-chain modified polyamino acid, wherein the polyamino acid comprises a backbone and a side chain; the main chain is polylysine or a copolymer formed by lysine and other amino acids; the other amino acids are selected from one or more of serine, threonine, tyrosine, and arginine, histidine, glycine, leucine, isoleucine, valine, phenylalanine, tryptophan, proline, asparagine, and glutamine;
at least part of the side chains respectively contain a group A and a group G, wherein the group A is-L3-S-S-C4-25Aliphatic hydrocarbon radical, L3Is C1-10An aliphatic alkylene radical, the group G being selected from the group G1 and/or the group G2, wherein the group G1 is terminated by a C1-10The polyethylene glycol group of alkoxy, the group G2 is a polyethylene glycol group with a biological functional group connected with the end group;
the group a or the group G is linked to an amino acid in the backbone via a linking group Y.
In one embodiment, said C4-25The aliphatic hydrocarbon group is C4-25Alkyl radical, C4-25Alkenyl radical, C4-25Alkynyl.
In one embodiment, L3Is C1-6An alkyl group.
In one embodiment, the linking group Y is the following group: -NH-CO-, -NH-, -N = CR1-、-N-CHR1-、-NH-CH2-CO-、-O-CO-、-O-、-O-CH2-any one of CO-. Wherein R is1Independently selected from H, C1-6An alkyl group. The first amino group or oxygen from the left in the above-mentioned linking group Y is derived from a reactive group such as an amino group or a hydroxyl group on the side chain of the polyamino acid.
In one embodiment, the linking group Y may be a direct bond (direct link) to the group a, or any spacer group may be present.
In one embodiment, the linking group Y may be a direct bond (direct link) to group G, or any spacer group may be present.
In one embodiment, the group G1 is-L1-PEG-L2-Z1-D, wherein PEG is a polyethylene glycol segment and D is C1-10Alkoxy radical, Z1Is a linking group, L1、L2Is a direct bond or a spacer group.
In one embodiment, the group G2 is-L1-PEG-L2-Z2-E, wherein PEG is a polyethylene glycol segment, E is a biofunctional group, Z2Is a linking group, L1、L2Is a direct bond or a spacer group.
In one embodiment, L1、L2For example, a direct bond, C1-10An alkyl group.
In one embodiment, the linking group Z1、Z2Comprises the following groups:
-CO-NH-、-CO-O-、-O-、-O-CH2-CO-、-NH-、-N=CR1-、-N-CHR1-、-NH-CH2-CO-、-S-S-、-S-CO-、-S-CH2-CO-orAny one of a connecting group obtained by click reaction of azido and alkynyl and a connecting group obtained by click reaction of tetrazine and double bond.
Wherein, the connecting group obtained by click reaction of the azido and the alkynyl is triazolyl or a derivative thereof; the connecting group obtained by click reaction of tetrazine and double bonds is diazacyclo or derivatives thereof.
In one embodiment, the number of repeating units of the polyethylene glycol segment is an integer between 1 and 600, preferably an integer between 2 and 300, and more preferably an integer between 4 and 200.
In one embodiment, the disulfide bond in the group a may be cleaved in a reducing environment.
In the present invention, the reducing environment comprises a reducing agent, such as one or more of a mercapto compound, a phosphino compound, a sulfite, a dithionite, and a thiosulfate; preferably selected from one or more of glutathione, cysteine, dithiothreitol, mercaptoethanol, cysteamine and tris- (2-carboxyethyl) phosphine.
In one embodiment, the alkoxy group in the group G1 is C1-6Alkoxy radicals, such as methoxy, ethoxy.
In one embodiment, the biofunctional group is a linker capable of binding to a biomolecule such as a protein, polypeptide, amino acid, etc., including a synthetic linker or a natural biomolecule.
In one embodiment, the binder comprises biotin which can bind to avidin; linkers that can be attached to the SNAP protein, such as benzylguanine and derivatives thereof; linkers that can be attached to CLIP proteins, such as benzyl cytosine and derivatives thereof; linkers (HaloTag Ligand (HTL)) that can be attached to a HaloTag protein, such as 6-chlorohexane and derivatives thereof; the derivative may be an oligoethylene glycol derivative having an ethylene glycol repeating unit number of less than 46.
In one embodiment, the natural biomolecule comprises at least one of a carbohydrate molecule, an RNA segment, an amino acid sequence.
Wherein the saccharide molecules are saccharide molecules capable of combining with receptor proteins and comprise monosaccharide, disaccharide and oligosaccharide; the monosaccharide is at least one of dihydroxyacetone, erythrose, threose, arabinose, ribose, deoxyribose, xylose, lyxose, glucose, mannose, fructose, galactose and rhamnose. The disaccharide is at least one selected from sucrose, lactose and maltose; the oligosaccharide is selected from at least one of maltotriose, melezitose, raffinose, gentianose, mannotriose and rhamnose, and at least one of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and delta-cyclodextrin which can be combined with other small molecules.
Wherein the RNA segment is a nucleotide or deoxynucleotide sequence which can be complementary with the biomolecule to be detected, such as a nucleic acid aptamer sequence which is 5-80 nucleotides and can be combined with protein.
Wherein the amino acid sequence is an amino acid sequence capable of binding to a protein, such as an antibody, and is about 2 to 100 amino acid residues in length, including influenza hemagglutinin HA amino acid sequence, FLAG amino acid sequence, myc-tag amino acid sequence, "C-tag" comprising-EPEA amino acid sequence, and amino acid "ALFA-tag" comprising SRLEEELRRRL.
In the invention, the antibody is at least one of polyclonal antibody, monoclonal antibody and nano antibody, and the antibody is an antibody derived from animals or an antibody prepared by expression of recombinant protein.
In one embodiment, the side chain modified polyamino acid may be one of the following: polyamino acids comprising group a and group G1, polyamino acids comprising group a and group G2, polyamino acids comprising group a, group G1 and group G2. In the polyamino acid, a polyamino acid side chain that is not modified may be present.
In one embodiment, the polyamino acid has a molar percentage of side chains containing group G1 and/or group G2 to the total amount of side chains ranging from 2% to 98%, preferably from 5% to 90%, more preferably from 10% to 80%.
In one embodiment, the number of side chains containing group a in the polyamino acid is from 2% to 98%, preferably from 5% to 90%, more preferably from 10% to 80% by mole of the total number of side chains.
In one embodiment, the molar percentage of the sum of the number of side chains containing a group a and the number of side chains containing group G1 and/or group G2 in the total number of side chains in the polyamino acid is 5% to 100%, preferably 20% to 100%, more preferably 40% to 100%, and may be, for example, 30% to 98%, 35% to 95%, or 40% to 90%.
In one embodiment, arginine, histidine, glycine, leucine, isoleucine, valine, phenylalanine, proline, tryptophan, asparagine, glutamine in the backbone can adjust the hydrophilicity and hydrophobicity, hydrogen bonding ability, and pH response of the polyamino acid based on the hydrophobic characteristics or molecular configuration, size, aromaticity, hydrogen bonding ability, pH response, etc. of its side chains.
In one embodiment, the backbone of the polyamino acid is poly-l-lysine.
In one embodiment, the backbone of the polyamino acid is artificially synthesized poly-d-lysine.
In one embodiment, the backbone of the polyamino acid is alpha-polylysine or epsilon-polylysine.
In one embodiment, the main chain of the polyamino acid is a copolymer of lysine and other amino acids, including any one of lysine-arginine copolymer, lysine-histidine copolymer, lysine-serine copolymer, lysine-threonine copolymer, lysine-tyrosine copolymer, lysine-serine-threonine copolymer, lysine-arginine-histidine copolymer, lysine-serine-threonine-tyrosine copolymer, lysine-glycine copolymer, lysine-leucine copolymer, lysine-isoleucine copolymer, lysine-valine copolymer, lysine-phenylalanine copolymer, and lysine-tryptophan copolymer.
In one embodiment, the molar percentage of lysine in the polyamino acid to the total amount of other amino acids and lysine is 0.1% to 100%, preferably 10% to 100%, more preferably 30% to 100%.
In one embodiment, the number of repeating units of the polyamino acid is an integer between 2 and 3000, preferably an integer between 3 and 1500, more preferably an integer between 4 and 1000, even more preferably an integer between 5 and 500.
In one embodiment, the side chain modified polyamino acid may be, for example, specifically:
the invention also provides a side chain modified polyamino acid, which is prepared by the following preparation method:
the polyamino acid with side chain having active group is connected with one end of C1-10Polyethylene glycol with reactive group x1 connected to the other end of alkoxy group and/or polyethylene glycol with biological functional group connected to one end and reactive group x2 connected to the other end, and C with reactive group x3 connected to the other end and activated disulfide bond1-10Reacting aliphatic hydrocarbon; wherein the reactive groups x1, x2 and x3 react with the active groups on the side chain of the polyamino acid, such that the end group is provided with C1-10Polyethylene glycol of alkoxy and/or biological functional group and aliphatic hydrocarbon containing activated disulfide bond group are connected to the side chain of polyamino acid; then the product is mixed with C4-25And (3) reacting aliphatic hydrocarbon mercaptan to prepare the side chain modified polyamino acid.
According to the invention, the activated disulfide bond is an-S-S-pyridyl group.
In one embodiment, said one end is connected to C1-10The polyethylene glycol having the reactive group x1 attached to the other end of the alkoxy group may be obtained commercially or may be prepared by methods conventional in the art.
In one embodiment, the polyethylene glycol having a biofunctional group attached to one end and a reactive group x2 attached to the other end is commercially available, or can be prepared by methods conventional in the art, such as the following:
reacting polyethylene glycol having a reactive group x2 attached to one end thereof and a reactive group x4 attached to the other end thereof with a biofunctional substance having a reactive group x5 attached thereto, wherein the reactive group x4 reacts with the reactive group x5, thereby attaching the biofunctional group to one end of the polyethylene glycol.
In one embodiment, the reactive groups x4, x5 are selected from, for example, hydroxyl, amino, carboxyl, aldehyde, ketone, ester, thiol, maleimide, α -halocarbonyl, alkyne, alkene, azide, tetrazine groups. Wherein the reactive groups x4 and x5 are reactive groups with each other and can react.
For example, an amino group is condensed with a carboxyl group to obtain an amide linking group, or an amino group is reacted with an aldehyde group or a ketone group to obtain a schiff base linking group, or an amino group is reacted with an ester group to obtain an amide linking group, or a hydroxyl group is condensed with a carboxyl group to obtain an ester linking group, or a hydroxyl group is dehydrated and condensed with a hydroxyl group to obtain an ether linking group, or maleimide and a thiol group are subjected to an addition reaction, or a thiol group is subjected to a substitution reaction with an α -halocarbonyl group, or an alkynyl group is subjected to a click reaction with an azide group to obtain a linking group, or an olefinic bond is subjected to a click reaction with a tetrazine group to obtain a linking group. Among them, the click reaction of an alkynyl group with an azido group is a "click chemistry" reaction known in the art, such as: azide-alkyne cycloaddition catalyzed by metal ions (e.g., cu (i)) (Sharpless reaction, with the alkynyl group typically at the end group), or cyclotension catalyzed azide-alkyne cycloaddition (SPAAC reaction, with the alkynyl group in the middle of the strained ring). The click reaction of an olefinic bond with a tetrazine group is a reaction known in the art, for example the cycloaddition reaction of a cyclic olefin with a tetrazine group.
Illustratively, when x4 is amino, x5 is at least one of carboxyl, aldehyde, ketone, ester, α -halocarbonyl; when x4 is hydroxyl, x5 is at least one of carboxyl, hydroxyl and alpha-halogenated carbonyl; when x4 is sulfhydryl, x5 is at least one of sulfhydryl, maleimide and alpha-halocarbonyl; when x4 is alkynyl, x5 is azido; when x4 is an olefinic bond, x5 is a tetrazinyl group. The reverse is also true.
The attachment between the polyethylene glycol and the terminal reactive groups x1, x2, x4 or the biofunctional group may be either direct, i.e. as a capping group, or may be by any spacer group, depending on the introduction of the reactive or biofunctional group onto the polyethylene glycol by any particular conventional method in the art. The spacer group between the polyethylene glycol and the reactive group, such as C, may be any spacer group that does not interfere with the preparation of the polyamino acids of the invention1-12Alkyl, ester, amide, ketone, and the like.
In one embodiment, in the above steps, the reaction is a conventional reaction step in the art, and the reaction temperature is, for example, 10 to 40 ℃.
In one embodiment, the reaction may be carried out under the promotion of a coupling agent. For example, an amino group may be condensed with a carboxyl group in the presence of a coupling agent to provide an amide linking group, or a hydroxyl group may be condensed with a carboxyl group in the presence of a coupling agent to provide an ester linking group. The coupling agent is, for example, a carbodiimide derivative selected from 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, or N, N-dicyclohexylcarbodiimide, and succinimide. The coupling agent further comprises a disulfide linkage structure, such as succinimide 3- (2-pyridyldithio) propionate, succinimide-oligo (ethylene glycol) -3- (2-pyridyldithio) propionate. The molar ratio of the coupling agent to the reactant is 1-500, preferably 1-100, more preferably 1-50, and still more preferably 1-20.
In one embodiment, the polyamino acid is polylysine, or a copolymer of lysine with other amino acids; the other amino acids are selected from one or more of serine, threonine, tyrosine, and arginine, histidine, glycine, leucine, isoleucine, valine, phenylalanine, tryptophan, proline, asparagine, and glutamine.
In the present invention, the side chain of the lysine contains an amino group; the side chains of the serine, the threonine and the tyrosine contain hydroxyl; the above groups can be modified by side chain functionalization through covalent coupling reaction.
In the invention, the arginine, histidine, glycine, leucine, isoleucine, valine, phenylalanine, proline, tryptophan, asparagine and glutamine can be used for adjusting the hydrophilicity and hydrophobicity, the hydrogen bonding capability and the pH value response of the polyamino acid according to the characteristics of the hydrophobic characteristics or molecular configuration, size, aromaticity, hydrogen bonding capability, pH value response and the like of the side chain of the arginine, histidine, glycine, leucine, isoleucine, valine, phenylalanine, proline, tryptophan, asparagine and glutamine.
In one embodiment, the biofunctional group is as defined above.
In one embodiment, said one end is connected to C1-10The structure of the polyethylene glycol with the other end of the alkoxy connected with a reactive group x1 is as follows: x1-L1-PEG-L2-Z1-D, wherein PEG is a polyethylene glycol segment and D is C1-10Alkoxy radical, Z1Is a linking group, L1、L2Is a direct bond or a spacer group, and the reactive group x1 is a hydroxyl group, a carboxyl group, an aldehyde group, a ketone group, an ester group, a maleimide group, an alpha-halocarbonyl group.
In one embodiment, the polyethylene glycol having a biofunctional group attached to one end and a reactive group x2 attached to the other end has the structure: x2-L1-PEG-L2-Z2-E, wherein PEG is a polyethylene glycol segment, E is a biofunctional group, Z2Is a linking group, L1、L2Is a direct bond or a spacer group, and the reactive group x2 is a hydroxyl group, a carboxyl group, an aldehyde group, a ketone group, an ester group, a maleimide group, an alpha-halocarbonyl group.
In one embodiment, the aliphatic hydrocarbon having a reactive group attached at one end x3 and an activated disulfide bond attached at the other end has the structure: x3-L3-S-pyridyl, the reactive group x3 being a hydroxyl, carboxyl, aldehyde, ketone, ester, maleimide, α -halocarbonyl group. L is3Is C1-10An aliphatic hydrocarbon group.
In one embodiment, the reactive groups x1, x2, x3 are selected from hydroxyl, carboxyl, aldehyde, ketone, ester, maleimide, α -halocarbonyl; the reactive groups x1, x2, x3 react with the active groups amino or hydroxyl on the side chain of the polyamino acid; specifically, an amino group and a carboxyl group are subjected to a condensation reaction to obtain an amide connecting group, or the amino group and an aldehyde group or a ketone group are subjected to a reaction to obtain a Schiff base connecting group, or the amino group and an ester group are subjected to a reaction to obtain an amide connecting group, or the amino group and an alpha-halocarbonyl group are subjected to a substitution reaction, or a hydroxyl group and a carboxyl group are subjected to a condensation reaction to obtain an ester connecting group, or the hydroxyl group and a hydroxyl group are dehydrated to be subjected to a condensation reaction to obtain an ether connecting group, or the hydroxyl group and an alpha-halocarbonyl group are subjected to a substitution reaction.
Illustratively, when the side chain of the polyamino acid contains an amino group, the reactive groups x1, x2, x3 are at least one of carboxyl, aldehyde, ketone, ester, α -halocarbonyl; when the side chain of the polyamino acid contains hydroxyl, the reactive groups x1, x2 and x3 are at least one of carboxyl, hydroxyl and alpha-halogenated carbonyl.
The invention also provides a preparation method of the side chain modified polyamino acid, which comprises the following steps:
the polyamino acid with side chain having active group is connected with one end of C1-10Polyethylene glycol with reactive group x1 connected to the other end of alkoxy group and/or polyethylene glycol with biological functional group connected to one end and reactive group x2 connected to the other end, and C with reactive group x3 connected to the other end and activated disulfide bond1-10Reacting aliphatic hydrocarbon; wherein the reactive groups x1, x2 and x3 react with the active groups on the side chain of the polyamino acid, such that the end group is provided with C1-10Polyethylene glycol of alkoxy and/or biological functional group and aliphatic hydrocarbon with activated disulfide bond at the end group are connected to the side chain of polyamino acid; then the product is mixed with C4-25And (3) reacting aliphatic hydrocarbon mercaptan to prepare the side chain modified polyamino acid.
The invention also provides the application of the side chain modified polyamino acid, which is used for preparing micelle.
The invention also provides a micelle, which comprises the side chain modified polyamino acid.
In one embodiment, the micelle is formed by dissolving the side chain-modified polyamino acid into a solvent.
Preferably, the side chain-modified polyamino acid is dissolved in water or a buffer solution having a pH of 3 to 8 so that the concentration thereof is 1 to 1000 times the critical micelle concentration to form the micelle.
In one embodiment, the micelle is composed of one side chain-modified polyamino acid described above, or a combination of two or more side chain-modified polyamino acids described above. The combination may be a combination of binary, ternary, or multiple side chain-modified polyamino acids, and the percentage of each side chain-modified polyamino acid in the composition is not particularly limited as long as the composition is capable of forming micelles.
In one embodiment, the critical micelle concentration of the side chain-modified polyamino acid is determined by methods known in the art, including, for example, conductance, surface tension, drop volume, ultrafiltration curve, single-point ultrafiltration, double-point ultrafiltration, uv spectrophotometry, dye adsorption, light scattering, fluorescence probe, and solubility.
In one embodiment, the micelles have a mean particle size of less than 300nm, preferably less than 200nm, more preferably less than 100nm, and even more preferably less than 80 nm.
In one embodiment, the size of the micelles is measured by methods known in the art, including, for example, dynamic laser scattering, fluorescence correlation spectroscopy, and scanning electron microscopy imaging.
The invention also provides a preparation method of the micelle, which comprises the following steps:
the polyamino acid with the modified side chain is dissolved in a solvent, and the concentration of the polyamino acid is 1-1000 times of the critical micelle concentration.
In one embodiment, the concentration is 1 to 1000 times the critical micelle concentration, preferably the concentration is 1 to 200 times the critical micelle concentration, more preferably the concentration is 1 to 50 times the critical micelle concentration, and even more preferably the concentration is 1 to 10 times the critical micelle concentration.
In one embodiment, the solvent is, for example, an aqueous solution or a buffer with a pH of 3-8, such as acetate buffer, phosphate buffer.
The invention also provides the use of the micelle in the coating and delivery of nucleic acid molecules.
The invention also provides a delivery system comprising a micelle and a nucleic acid molecule, the nucleic acid molecule being located within the micelle.
In one embodiment, the nucleic acid molecule comprises RNA and DNA.
In one embodiment, the nucleic acid molecule may be a vaccine or a drug, i.e. the nucleic acid molecule is an RNA vaccine, an RNA drug, a DNA vaccine.
In one embodiment, the RNA is single-stranded RNA or double-stranded RNA.
The nucleic acid molecule of the invention is used for treating or preventing infectious diseases, tumors, rare diseases, other protein deficiency diseases and the like, or is used for beautifying, resisting aging and the like. The RNA target sequences for the treatment of infectious diseases according to the invention are the gene sequences of proteins or protein fragments of the receptor binding region of the virus, the capsid protein of the virus or other conserved regions of the virus.
In one embodiment, the molar ratio of the nucleic acid molecule to the micelle-forming side-chain modified polyamino acid is from 0.001 to 1000:1, preferably from 0.01 to 100:1, more preferably from 0.1 to 10: 1.
In one embodiment, the delivery system optionally comprises an adjuvant selected from at least one of a naturally occurring phospholipid molecule, cholesterol, an amino acid, a polypeptide, an ionic surfactant, and a non-ionic surfactant.
In one embodiment, the molar ratio of adjuvant to nucleic acid molecule is 0.001-8000:1, preferably 0.01-4000:1, more preferably 0.1-1000: 1.
The present invention also provides a method of preparing a delivery system, the method comprising the steps of:
and (3) contacting the solution containing the micelle with nucleic acid molecules, and incubating the mixed solution to prepare the delivery system.
Wherein mechanical stirring, oscillation, thermal refluxing or ultrasonic dispersion is used in the contact process.
The present invention also provides a method of preparing a delivery system, the method comprising the steps of:
and mixing the side chain modified polyamino acid with nucleic acid molecules to form a mixed solution, and preparing to obtain the delivery system.
The invention also provides freeze-dried powder which is obtained by evaporating the solvent in the delivery system to dryness.
In one embodiment, the lyophilized powder is reconstituted in a solvent to form a delivery system at the time of use.
Wherein the solution containing the micelles may be, for example, an organic solution containing micelles or an aqueous solution containing micelles, and the solvent of the organic solution is not particularly limited as long as it can dissolve the material, and may be optionally one of alcohol, ether, ketone, ester, amide, sulfoxide, alkane, cycloalkane, aromatic hydrocarbon, chloroalkane, or a mixture thereof.
[ terms and explanations ]
The terms "side chain-modified polyamino acid" and "polyamino acid" in the present invention are interchangeable.
The "aliphatic hydrocarbon" referred to herein may also be referred to as an aliphatic compound, and refers to a hydrocarbon having a structure not containing an aromatic ring, in which carbon atoms are arranged in a straight chain, a branched chain or a cyclic structure, and is referred to as a straight chain aliphatic hydrocarbon, a branched chain aliphatic hydrocarbon or an alicyclic hydrocarbon, respectively. The aliphatic compound may be an alkane, alkene or alkyne. The aliphatic hydrocarbon of the present invention may have 1 to 40 carbon atoms.
The alkyl group in the present invention represents a linear, branched or cyclic alkyl group having 1 to 40 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, etc.
The alkenyl group in the present invention represents a linear, branched or cyclic alkenyl group having 1 to 40 carbon atoms, for example, ethylene, propylene, isopropylene, butene, etc. Preferably, the number of double bonds is an integer from 1 to 6.
The alkynyl group in the present invention represents a linear, branched or cyclic alkynyl group having 1 to 40 carbon atoms, for example, acetylene, propyne, butyne and the like. Preferably, the number of acetylenic bonds is an integer from 1 to 6.
The amino group of the present invention represents the group-N (R)2)2Wherein R is2Independently selected from H, C1-6An alkyl group.
The ester group according to the invention represents the group-CO-OR3Wherein R is3Is C1-6An alkyl group.
The term "reactive group" may also be referred to as a "reactive group," which refers to a functional group that can form a chemical bond with another "reactive group. Suitable chemical bonds are well known in the art and may be, for example: hydroxyl, amino, carboxyl, aldehyde, ketone, ester, sulfhydryl, maleimide, alpha-halocarbonyl, alkynyl, olefinic bond, azido and tetrazine.
The term "linking group" refers to a group that links any two groups together, which is a group formed by the reaction of two "reactive groups".
The term "spacer group" means a group which may be formed when a reactive group or the like is introduced into the end of a polyethylene glycol chain by a conventional reaction. The groups depend on the reagents used to introduce the groups.
The term "binder" refers to a substance capable of binding to a biological molecule such as a protein, polypeptide, amino acid, etc., by means of, for example, covalent bonds, non-covalent bonds, etc.
The term "linker" may also be referred to as a "Ligand linker," and in english Ligand, refers to a group that is covalently linked to a protein, amino acid, antibody, polypeptide, or the like.
The term "nucleic acid" refers to deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
The invention has the beneficial effects that:
the invention provides a polyamino acid for delivering nucleic acid molecules, a preparation method and application thereof. The side chain modified polyamino acid has the following advantages:
(1) the extensive presence of glutathione and sulfhydryl metabolites in the cytoplasm of cells makes a reducing environment ubiquitous in the cytoplasm. Lysosomes formed after endocytosis of the nanocarrier by the cell are in a typical reducing environment and at low pH. The main chain structure and the side chain modification of the polyamino acid micelle carrier are comprehensively optimized, and the disulfide bond cracked in a reducing environment is introduced into the side chain, so that the response of the micelle to the reducing environment and the low pH value in cytoplasm can be promoted, and the mRNA vaccine can be helped to actively escape from a 'lysosome trap' to enter the cytoplasm. Active cleavage of the nanocarriers can release mRNA more efficiently than passive osmotic pressure dominated escape processes.
(2) The main chain and side chain structures and the connection mode thereof can be flexibly selected, and the number and the types of hydrophilic groups, charge characteristics and hydrophobic groups are adjusted, so that the prepared polyamino acid micelle has good biocompatibility and targeted delivery efficiency.
(3) The charge polarity of the main chain of the polyamino acid is electropositive, and the reactive groups of the side chain can be amino or hydroxyl respectively. The charge distribution of the main chain is adjusted through the quantity and distribution of other copolymerized amino acids such as arginine, histidine, serine and the like, and the efficient and controllable wrapping of electronegative RNA is realized. Charge modulation on the backbone promotes the pH response of the micelle, helping RNA escape from the "lysosomal trap" into the cytosol.
(4) The hydrophobic part of the side chain is controlled by quantifying the chain length, the saturation and the number of the fatty chains modified by the side chain, the volume and the association strength of the hydrophobic part are accurately adjusted, the volume of the hydrophilic part is adjusted by selecting the chain length and the number of branches of the polyethylene glycol polymer, and the two are cooperated to realize the accurate adjustment and control of the size and the stability of the polyamino acid micelle. The polyamino acid micelle has small size and good tissue penetrability.
(5) Due to the similarity of RNA and DNA in structure and electronegativity, the basic charge, size and stability of the micelle are flexibly adjusted, and a packaging and delivery system is efficiently constructed, so that the efficient packaging and delivery of effective components of nucleic acids such as mRNA vaccines, RNA medicines, DNA vaccines and the like can be realized.
(6) A plurality of same biological functional groups are introduced through side chain modification of functional macromolecules, and the functional macromolecules comprise targeted binding effectors such as micromolecule binders, proteins and antibodies, and the high-efficiency and stable binding of a delivery system to target tissues and parts is realized by utilizing multivalent functionalization.
(7) Different biological functional groups are introduced through the modification of the side chains of functional macromolecules, the functional groups comprise targeted binding effectors such as micromolecule binders, proteins and antibodies, the specific binding of a delivery system to target tissues and parts is realized through a composite-synergistic action mechanism of different functional groups, and the targeted delivery effect is improved.
Drawings
FIG. 1 measurement result of critical micelle concentration of polyamino acid prepared in example 12.
FIG. 2 dynamic laser light scattering results for micelles formed by the polyamino acid prepared in example 12, with the size distribution shown in logarithmic scale.
Fig. 3 results of dynamic laser light scattering of polyamino acid micelles containing mRNA vaccine prepared in example 16.
Fig. 4 results of dynamic laser light scattering of polyamino acid micelles containing mRNA vaccine prepared in example 19.
FIG. 5 results of dynamic laser light scattering experiments before and after loading of Kjeldahl targeting antibodies for multivalent targeting vaccine H7N9-BT21 (A) and monovalent targeting vaccine H7N9-BT1 (B).
FIG. 6 gel electrophoresis chromatogram of reverse transcription-PCR analysis of IL-6 receptor stable transfected cells of HEK 293T. Wherein, 1 is the cell added with the multivalent targeted H7N9-BT21 mRNA vaccine, 2 is the cell added with the monovalent targeted H7N9-BT1 mRNA vaccine, and 3 is the control group without vaccine.
FIG. 7 results of dynamic laser light scattering experiments on the oxidation-reduction conditional response of the binary polypeptide complex biofunctionalized polyamino acid mRNA vaccine of example 12. The solid line and the black squares show the particle size distribution of the polyamino acid mRNA vaccine, and the dashed line and the grey squares are the particle sizes of the polyamino acid mRNA vaccine in a 5mM DTT reducing environment.
Detailed Description
The preparation method of the present invention will be described in further detail with reference to specific examples. It is to be understood that the following examples are only illustrative and explanatory of the present invention and should not be construed as limiting the scope of the present invention. All the technologies realized based on the above-mentioned contents of the present invention are covered in the protection scope of the present invention.
The experimental methods used in the following examples are all conventional methods unless otherwise specified; reagents, materials and the like used in the following examples are commercially available unless otherwise specified.
The buffers used in the examples described below were commonly used buffer solutions including phosphate buffer, HEPES buffer, and Tris buffer, water was sterilized in milliq deionized water with a conductivity of 18.2 ohms cm.
The percentages (%) used in the examples below are in mol%.
Optionally indicating the presence or absence of the stated feature, and also indicating that the stated feature must be present, although the particular choice may be arbitrary.
Example 1 preparation of the polyamino acid PLL-SSMO25-PEG2000-Biotin20
10 mg of a hydrobromide salt of α -poly-L-lysine (a hydrobromide salt of PLL, average molecular weight 22500 Dalton) was weighed and dissolved in 150 μ L of phosphate buffer solution (pH 7.4) to obtain a solution (A). 20 mg of polyethylene glycol 2000 (BIOTIN-PEG 2000-SCM, polyethylene glycol average molecular weight 2000 Dalton, available from Kyoto Kai technologies, Inc.) with end group modified BIOTIN and succinimide carboxymethyl ester was weighed and dissolved in 150 μ L of tetrahydrofuran (analytical reagent, Nanjing reagent, Inc.). To the resulting solution was added 3.8 mg of succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, semenfei) coupling agent to obtain a mixture solution (B). The solution (A) and the solution (B) were mixed in a test tube, and reacted for 4 hours at room temperature with shaking, after which 2.5. mu.L of n-octylmercaptan (MO, analytically pure, molecular weight 146, density 0.84 g/L, Beijing Bailingwei) of 1.2 times reaction equivalent was added to the resulting mixed solution. Shaking at room temperature overnight, adding 100 mu L of Tris buffer solution with pH of 8.0, and continuing to shake for 1 hour to terminate the reaction. The reaction solution was dialyzed against deionized water for 24 hours (MWCO 50 ten thousand daltons). The obtained solution is frozen and then placed in a freeze dryer to prepare 19 mg of freeze-dried powder. The freeze-dried powder is 25% of disulfide bond n-octane and 20% of polyethylene glycol 2000-Biotin graft-modified functional polyamino acid, the polyamino acid is named as PLL-SSMO25-PEG2000-Biotin20, and the specific structural formula is shown as follows.
The number of side chains of a polyamino acid to which no other component is bonded is represented by n, the number of side chains of a polyamino acid to which polyethylene glycol is bonded is represented by p, the number of repeating units of polyethylene glycol is represented by q, and the number of side chains of a polyamino acid to which a disulfide bond-containing hydrophobic component is bonded is represented by m, i.e., m/(m + n + p) =0.25, and p/(m + n + p) = 0.2.
Example 2 preparation of the polyamino acid PLL-SSMO25-PEG3500-Biotin20
10 mg of PLL hydrobromide (average molecular weight 22500 daltons) was weighed into a 2 ml centrifuge tube and dissolved in 150. mu.L phosphate buffer (pH 7.4) to obtain solution (A). 33 mg of polyethylene glycol 3500 (BIOTIN-PEG 3500-SCM, polyethylene glycol average molecular weight 3500 Dalton, available from Kyoto Keka science and technology Co., Ltd., Beijing) with the end group-modified BIOTIN and succinimide carboxymethyl ester was weighed and dissolved in 150. mu.L of tetrahydrofuran. To the resulting solution was added 3.8 mg of succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, semenfei) coupling agent to obtain a mixture solution (B). The solution (A) and the solution (B) were mixed in a test tube, and reacted for 4 hours at room temperature with shaking, after which 2.5. mu.L of n-octylmercaptan (MO, analytically pure, molecular weight 146, density 0.84 g/L, Beijing Bailingwei) of 1.2 times reaction equivalent was added to the resulting mixed solution. The reaction product was prepared according to the method of example 1 and lyophilized to obtain 23 mg of lyophilized powder. The white powder is functionalized polyamino acid grafted and modified by 25 percent of disulfide bond n-octane and 20 percent of polyethylene glycol 3500-Biotin, and the polyamino acid is named as PLL-SSMO25-PEG3500-Biotin 20.
Example 3 preparation of the polyamino acids PLL-SSDT25-PEG3500-Biotin20
The same as example 2, except that 27 mg of lyophilized powder was prepared using 3.0 μ L of n-decanethiol (DT, molecular weight 174, Sigma Aldrich Co.). The white powder is 25% disulfide bond n-decane and 20% polyethylene glycol 3500-Biotin graft modified functionalized polyamino acid which is named as PLL-SSDT25-PEG3500-Biotin 20.
The number of side chains of a polyamino acid to which no other component is bonded is represented by n, the number of side chains of a polyamino acid to which polyethylene glycol is bonded is represented by p, the number of repeating units of polyethylene glycol is represented by q, and the number of side chains of a polyamino acid to which a disulfide bond-containing hydrophobic component is bonded is represented by m, i.e., m/(m + n + p) =0.25, and p/(m + n + p) = 0.2.
Example 4 preparation of the polyamino acid PLL-SSMO50-PEG3500-Biotin50
The same as in example 2, except that 82 mg of terminal group-modified succinimide carboxymethyl ester and biotin polyethylene glycol 3500 were weighed, dissolved in 150. mu.L of tetrahydrofuran, and 7.6 mg of succinimide 3- (2-pyridyldithio) propionate coupling agent was added to obtain a solution (B). Adding 5.0 muL of n-octanethiol (MO) into the mixture (B), and preparing white freeze-dried powder which is functionalized polyamino acid grafted and modified by 50% of disulfide bond n-octane and 50% of polyethylene glycol 3500-Biotin and is named as PLL-SSMO50-PEG3500-Biotin50 according to the method in the example 1.
Example 5 preparation of the polyamino acids ε PLL-SSMO25-PEG5000-Biotin30
10 mg of hydrobromide of ε -poly-L-lysine (hereinafter referred to as hydrobromide of ε PLL, average molecular weight 50000 daltons) was weighed in a 2 ml centrifuge tube and dissolved in 150. mu.L of phosphate buffer to obtain a solution (A). 60 mg of polyethylene glycol 5000 (BIOTIN-PEG 5000-SCM, average molecular weight 5000 Dalton, available from Kyoto Kai technologies, Ltd.) with end group-modified BIOTIN and succinimide carboxy methyl ester as terminal groups was weighed and dissolved in 150 μ L of tetrahydrofuran. To the resulting solution was added 3.8 mg of succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, semenfei) coupling agent to obtain a mixture solution (B). The solution (A) and the solution (B) were mixed in a test tube, and the reaction was carried out with shaking at room temperature for 4 hours, after which 2.5. mu.L (MO, analytically pure, molecular weight 146) of n-octylthiol of 1.2 times reaction equivalent was added to the resulting mixed solution. After shaking overnight at room temperature for 8 hours, 100. mu.L of 20 mM Tris buffer pH 8.0 was added, and the reaction was terminated by continuing shaking for 1 hour. The reaction solution was dialyzed against deionized water for 24 hours (MWCO 50 ten thousand daltons). Freezing the obtained solution, and placing in a freeze dryer to obtain 39 mg of freeze-dried powder, and storing at-20 deg.C under sealed condition. The white powder is 25% of disulfide bond n-octane and 30% of polyethylene glycol 5000-Biotin graft modified functional polyamino acid epsilon PLL-SSMO25-PEG5000-Biotin30, and the structural formula is as follows.
The number of side chains of a polyamino acid to which no other component is bonded is represented by n, the number of side chains of a polyamino acid to which polyethylene glycol is bonded is represented by p, the number of repeating units of polyethylene glycol is represented by q, and the number of side chains of a polyamino acid to which a disulfide bond-containing hydrophobic component is bonded is represented by m, i.e., m/(m + n + p) =0.25, and p/(m + n + p) = 0.3.
Example 6 preparation of the polyamino acids ε PLL-SSMO25-PEG5000-N3
10 mg of Epsilon PLL (average molecular weight 50000 daltons) was weighed and dissolved in 150. mu.L of phosphate buffer to obtain a solution (A). 72 mg of polyethylene glycol 5000 (AZIDE-PEG 5000-SCM, average molecular weight 5000 Dalton, available from Kyoto Keyka science and technology Co., Ltd.) of terminal group-modified AZIDE salt and succinimide carboxymethyl ester was weighed and dissolved in 150 μ L of tetrahydrofuran. To the resulting solution was added 3.8 mg of succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, semenfei) coupling agent to obtain a mixture solution (B). The solution (A) and the solution (B) were mixed in a test tube, and the reaction was carried out for 4 hours at room temperature with shaking, after which 2.5. mu.L (MO, analytically pure, molecular weight 146) of n-octylthiol was added to the resulting mixed solution. The reaction solution was continued to be mixed in a shaker at room temperature. The product was prepared as described in example 5, lyophilized to 31 mg of lyophilized powder and stored sealed at-20 ℃. The white powder is polyamino acid grafted and modified by 25 percent of disulfide bond N-octane and 30 percent of polyethylene glycol 5000-azide, and the polyamino acid is named as epsilon PLL-SSMO25-PEG 5000-N3.
The number of side chains of a polyamino acid to which no other component is bonded is represented by n, the number of side chains of a polyamino acid to which polyethylene glycol is bonded is represented by p, the number of repeating units of polyethylene glycol is represented by q, and the number of side chains of a polyamino acid to which a disulfide bond-containing hydrophobic component is bonded is represented by m, i.e., m/(m + n + p) =0.25, and p/(m + n + p) = 0.3.
Example 7 preparation of the polyamino acid PLL-SSDDT25-PEG2000-OMe37
10 mg of a PLL hydrobromide salt (average molecular weight 22500 daltons) was weighed into a 2 ml centrifuge tube and dissolved in 150. mu.L of phosphate buffer to obtain a solution (A). 36 mg of polyethylene glycol (M-PEG 2000-SCM, average molecular weight 2000 Dalton, available from Kyork technology Co., Ltd.) with terminal group-modified methoxy group and succinimide carboxymethyl ester was weighed and dissolved in 150 μ L of tetrahydrofuran. To the resulting solution was added 3.8 mg of succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, semenfei) coupling agent to obtain a mixture solution (B). The solution (A) and the solution (B) were mixed in a test tube, and the reaction was carried out with shaking at room temperature for 4 hours, after which 3.5. mu.L of n-dodecylmercaptan (DDT, molecular weight 202, Sigma Aldrich Co.) was added to the resulting mixed solution, and the reaction solution was continued to be mixed overnight with shaking in a test tube at room temperature. In a similar manner to example 1, 26 mg of a white lyophilized powder was obtained. The white powder was 25% disulfide-bonded n-dodecane and 37% polyethylene glycol 2000-methoxy graft-modified polyamino acid, which was named PLL-SSDDT25-PEG2000-OMe 37. The specific structural formula is shown as follows.
The number of side chains of a polyamino acid to which no other component is bonded is represented by n, the number of side chains of a polyamino acid to which polyethylene glycol is bonded is represented by p, the number of repeating units of polyethylene glycol is represented by q, and the number of side chains of a polyamino acid to which a disulfide bond-containing hydrophobic component is bonded is represented by m, i.e., m/(m + n + p) =0.25, and p/(m + n + p) = 0.37.
Example 8 preparation of the polyamino acid PLL-SSDDT25-PEG2000-OMe75
The same as example 7, except that 73 mg of polyethylene glycol (M-PEG 2000-SCM, average molecular weight 2000 Dalton, available from Kyoto Kamiiki technologies, Inc.) having a terminal-modified methoxy group and a succinimide carboxy methyl ester was weighed out. 47 mg of a white lyophilized powder was obtained which was 25% disulfide-bonded n-dodecane and 75% polyethylene glycol 2000-methoxy graft-modified polyamino acid, designated PLL-SSDDT25-PEG2000-OMe 75.
Example 9 preparation of the polyamino acid PLL-SSDT25-PEG2000-OMe37
Same as example 7, except that 3.0 μ L of n-decanethiol (DT, molecular weight 174, SigmaAldrich Co.) was used, 20 mg of a white lyophilized powder was prepared which was 25% disulfide n-decane and 37% polyethylene glycol 2000-methoxy graft modified polyamino acid designated PLL-SSDT25-PEG2000-OMe 37.
Example 10 preparation of the polyamino acid PLL-SSMO25-PEG2000-OMe30-PEG2000-BG30
Weighing 96 mg of polyethylene glycol (SCM-PEG 2000-SCM, PEG average molecular weight 2000 Dalton, purchased from Kyork science and technology Co., Ltd.) with an end group modified by bis-succinimide carboxymethyl ester and a linker O6- [4- (aminomethyl) benzyl ] guanine (abbreviated as BG, purchased from Santa Cruz Biotechnology Co., Ltd.) of 10 mg of SNAPTag protein, dissolving the mixture in anhydrous 200 muL tetrahydrofuran, adding 4 muL triethylamine, reacting for 4 hours under nitrogen protection at room temperature, adding deionized water for 30 minutes, and terminating the reaction. The mixture was placed in a vacuum oven and the organic solvent was removed at 60 ℃. The reaction product was separated on a G200 silica gel chromatography plate with the mobile phase dichloromethane: and collecting a product strip at an Rf value of 0.25 of ethyl acetate (80: 20 by volume) to obtain 41 mg of oily substance COOH-PEG2000-BG, dissolving the oily substance COOH-PEG2000-BG in 200 mu L of tetrahydrofuran, and storing the oily substance away from light.
7.5 mg of poly-L-lysine hydrobromide (PLL hydrobromide, average molecular weight 22500 Dalton) was weighed out and dissolved in 100. mu.L of 5mM HEPES buffer solution (pH 7.4) to obtain solution (A). 24 mg of polyethylene glycol (M-PEG 2000-SCM, polyethylene glycol average molecular weight 2000 Dalton, purchased from Kyork science and technology Co., Ltd.) having methoxy and succinimide ester at both ends thereof were weighed in a small glass vial, dissolved in 150. mu.L of tetrahydrofuran, 114. mu.L of the above prepared tetrahydrofuran solution of COOH-PEG2000-BG was added, and 3.8 mg of succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, Saimer fly) coupling agent was added to the obtained solution to obtain a mixture solution (B). The solution (A) and the solution (B) were mixed in a test tube, and the reaction was carried out for 4 hours at room temperature with shaking, after which 2.5. mu.L of n-octylmercaptan (MO, analytically pure, molecular weight 146, density 0.84 g/L, Bailingwei, Beijing) was added to the resulting mixed solution. The reaction solution was continued to be shaken overnight in a shaker at room temperature in a test tube, and 100 μ L of deionized water was added for 30 minutes to terminate the reaction. The reaction solution was dialyzed for 24 hours (MWCO 50 ten thousand daltons). Lyophilizing to obtain 31 mg lyophilized powder. The freeze-dried powder is polyamino acid graft-modified by 25% of disulfide bond n-octane, 30% of polyethylene glycol 2000-methoxyl and 30% of ligand linker of polyethylene glycol 2000-SNAPTag protein, and the polyamino acid is named as PLL-SSMO25-PEG2000-OMe30-PEG2000-BG 30. The specific structural formula is shown as follows.
Wherein the number of side chains of the polyamino acid to which no other component is attached is represented by n, the number of side chains of the polyamino acid to which polyethylene glycol-methoxy groups are attached is represented by p, the number of repeating units of polyethylene glycol is represented by q, the number of side chains of the polyamino acid to which polyethylene glycol-BG functional groups are attached is represented by r, the number of repeating units of polyethylene glycol is represented by t, and the number of side chains of the polyamino acid to which disulfide bond-containing hydrophobic components are attached is represented by m, that is, m/(m + n + p + r) =0.25, p/(m + n + p + r) =0.3, and r/(m + n + p + r) = 0.3.
Example 11 preparation of the polyamino acid PLL-SSMO25-PEG3500-HA15-PEG3500-ALFAtag15 containing a Complex functionalized group of a binary polypeptide
7.5 mg of poly-L-lysine (PLL, average molecular weight 22500 daltons) was weighed out in a plastic vial and dissolved in 200 μ L of HEPES buffer (100 mM, pH 7.4) to give solution (A). 42 mg of polyethylene glycol (MAL-PEG 3500-SCM, PEG average molecular weight 2000 Dalton, purchased from Kyork science and technology Co., Ltd.) with end group modification of maleimide and succinimide carboxymethyl ester respectively, 6.5 mg of polypeptide lyophilized powder (HA-tag, N-terminal acetyl modification, molecular weight 1.3 kDa) with amino acid sequence of CYPYDVPDYA, and 8.5 mg of polypeptide lyophilized powder (ALFA-tag, N-terminal acetyl modification, molecular weight 1.9 kDa) with amino acid sequence of CPSRLEEELRRRLTE were weighed. This was dissolved in 200 μ L of HEPES buffer solution (5 mM HEPES) to adjust the pH of the solution to 6.0, to obtain a solution (B). And (3) oscillating for 10 minutes at room temperature to obtain polyethylene glycol solutions with end groups respectively containing HA polypeptide, ALFA-tag polypeptide binary composite functional groups and succinimide carboxymethyl ester, adding the polyethylene glycol solutions into the solution (A), and oscillating for 4 hours at room temperature. 3.8 mg of a succinimide 3- (2-pyridyldithio) propionate (SPDP, molecular weight 312, Sammerfei) coupling agent was added to the resulting mixed solution, and the reaction was carried out at room temperature for 4 hours with shaking, after which 2.5. mu.L (MO, analytical purity, molecular weight 146, density 0.84 g/L, Beijing Bailingwei) of n-octylmercaptan was added to the resulting mixed solution. The reaction solution was continued to be shaken overnight in a shaker at room temperature in a test tube, and 100 μ L of deionized water was added for 30 minutes to terminate the reaction. The reaction solution was dialyzed for 24 hours (MWCO 50 ten thousand daltons). Lyophilizing to obtain 37 mg lyophilized powder. The freeze-dried powder is polyamino acid subjected to binary composite functional graft modification by 25% of disulfide bond n-octane, 15% of polyethylene glycol 3500-HA-Tag and 15% of polyethylene glycol 3500-ALFA-Tag, and the polyamino acid is named as PLL-SSMO25-PEG3500-HA15-PEG3500-ALFAtag 15.
Wherein the number of side chains of the polyamino acid to which no other component is linked is represented by n, the number of side chains of the polyamino acid to which a side chain of polyethylene glycol-HA-tag is linked is represented by p, the number of repeating units of polyethylene glycol is represented by q, the number of side chains of the polyamino acid to which a side chain of polyethylene glycol-AFLA-tag is linked is represented by r, the number of repeating units of polyethylene glycol is represented by t, and the number of side chains of the polyamino acid to which a disulfide bond-containing hydrophobic component is linked is represented by m, that is, m/(m + n + p + r) =0.25, p/(m + n + p + r) =0.15, and r/(m + n + p + r) = 0.15.
Example 12 preparation and characterization of polyamino acid micelles
Using polylysine PLL-SSMO25-PEG2000-Biotin20 prepared in example 1 as an example, the critical micelle concentration CMC of polyamino acid micelles is determined by a probe steady state fluorescence emission method and the hydration diameter of the micelles is measured by a dynamic laser scattering method.
Probe pyrene (product of Sigma, gold tag, without further purification) was dissolved in anhydrous methanol to prepare a solution of 1.0X 10-4The mol/L solution is ready for use. Putting 5 mu L of pyrene methanol solution into a series of 5 mL volumetric flasks, introducing nitrogen to blow the methanol for drying, sequentially adding 5 mL of PLL-SSMO25-PEG2000-Biotin20 aqueous solution with different concentrations, putting the aqueous solution into an ultrasonic bath for dispersing for 1 hour, and taking 1mL of sample solution for measuring the fluorescence emission spectrum of pyrene. The fluorescence spectrum was measured with a Hitachi F-4500 fluorescence spectrophotometer, Japan, with an excitation wavelength of 335 nm, a slit width of 5 nm, an emission wavelength of 2.5 nm, a detector bias of 700V, and an experimental temperature of 22. + -. 1 ℃.
FIG. 1 shows the fluorescence emission spectrum change of pyrene in different concentrations of PLL-SSMO25-PEG2000-Biotin20 aqueous solution. The ratio (I) of the fluorescence intensity of the first peak (373 nm) to the third peak (384 nm) of pyrene1/ I3A) in FIG. 1 reflects the polarity change of the microenvironment around the pyrene molecule.
This ratio decreases successively with increasing concentration of the polyamino acid PLL-SSMO25-PEG2000-Biotin20 in aqueous solution (B in FIG. 1). When the concentration of the polyamino acid is increased to a certain value, the curve has mutation, the mutation indicates the change of the polarity of the environment where pyrene is located, and PLL-SSMO25-PEG2000-Biotin20 micelles are formed. Thus, the first mutation point corresponds to the CMC value of PLL-SSMO25-PEG2000-Biotin 20. The critical micelle concentration of PLL-SSMO25-PEG2000-Biotin20 was determined to be 2.1 mg/mL by this method. When the concentration of PLL-SSMO25-PEG2000-Biotin20 in aqueous solution is more than the value, micelle can be formed.
PLL-SSMO25-PEG2000-Biotin20 aqueous solution (concentration is more than CMC) with concentration of 3.0 mg/mL is prepared, and dynamic laser scattering experiment is carried out on 1mL solution. The hydrated diameter of the micelles was measured to be 97. + -.35 nm using Zetasizer Nano ZS ZEN3600 from Malvern Instruments, UK, and the results are shown in FIG. 2.
Example 13 preparation of avian influenza virus H7N9 subtype mRNA vaccine
In the first step, a DNA template is synthesized. To prepare an mRNA vaccine, DNA sequences are first synthesized for subsequent in vitro transcription. The gene sequence segment of avian influenza virus A/Shanghai/02/2013(H7N9) polymerase PB2 was selected as the target antigen sequence (gene sequence-1). The target antigen sequence is optimized by GC content (the optimization method is shown in mol. ther. 23, 1456-1464 (2015)), and an untranslated region regulatory element (i) 5 'UTR (beta-globin-1) is added at the 5' end:
CAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACC。
adding an untranslated region regulatory element (ii) at the 3 'end of the protein, (2 beta-globin) 3' UTR:
AGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGC
the sequences in (i) the 5 ' UTR can inhibit 5 ' -exonucleolytic degradation, and (ii) the 3 ' UTR can inhibit mRNA noradenylation to enhance mRNA stability and translation efficiency. (ii) further adding 70 repeated adenosines and 30 repeated cytosines at the 3' end to form (iii) Poly-a and Poly-C tails to enhance mRNA stability:
TTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATATTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATTGGAATT
and (3) synthesizing all the DNA sequences into a linear template according to the assembly sequence of 5 'UTR-target sequence-3' UTR-PolyA-PolyC, and carrying out in-vitro transcription of the next step.
Second, in vitro transcription. In the CAP analog (m)7GpppG) was prepared in vitro using T7 polymerase to transcribe the prepared DNA template to produce a "capped" mRNA. Subsequently, mRNA was purified using the MEGAclear Transcription clear-Up Kit (purchased from Sonofibrino corporation, Waltham, MA, USA). The resulting sample can be used immediately to form micelle encapsulated formulations or lyophilized for storage.
Example 14 preparation of mRNA vaccine for influenza A virus H1N1
In the first step, a DNA template is synthesized. The gene sequence of HA (Gene sequence-2) of hemagglutinin of influenza virus A/Puerto Rico/8/1934H 1N1 was used as the DNA sequence of the antigen of interest. After the GC content of the target gene sequence is optimized (see mol. ther. 23, 1456-1464 (2015)), an untranslated region regulatory element (i) 5 'UTR (beta-globin-2) is added at the 5' end:
AGAGCGGCCGCTTTTTCAGCAAGATTAAGCCCAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACC
3 '-end addition of untranslated region regulatory element (ii) 3' UTR (2 β -globin):
AGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGC
(ii) further adding (iii) a Poly-A tail and a Poly-C tail comprising repeated adenosine and repeated cytosine sequences:
TTAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATATTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCTAGACAATTGGAATT
and (3) synthesizing all the DNA sequences into a linear template according to the assembly sequence of 5 'UTR-target sequence-3' UTR-PolyA-PolyC, and carrying out in-vitro transcription of the next step.
Second, in vitro transcription. In the CAP analog (m)7GpppG) was prepared as a "capped" mRNA by in vitro transcription of the prepared DNA template using T7 polymerase. Subsequently, mRNA was purified using the MEGAclear Transcription clear-Up Kit (purchased from Sonofibrino corporation, Waltham, MA, USA). The mRNA vaccine of influenza A virus H1N1 is obtained by the in vitro transcription, capping and purification, and is used for forming micelle coating preparation or freeze-drying preservation.
Example 15 preparation of mRNA vaccine for coronavirus SARS-Cov-2
The DNA template was synthesized according to the procedure described in example 14, first step. The Gene sequence of the surface spike protein receptor binding region of SARS-CoV-2 coronavirus (NIH Gene ID: 43740568, Gene sequence-3) was used as the DNA sequence of the antigen of interest. The target gene sequence is optimized by GC content, and a linear template is synthesized by adding an untranslated region regulatory element (i) 5 'UTR (beta-globin-2), (ii) 3' UTR (2 beta-globin), and (iii) Poly-A tail and Poly-C tail of repeated adenosine and cytosine. And secondly, the obtained DNA template is subjected to in vitro transcription, capping and purification to obtain the mRNA vaccine of the coronavirus SARS-Cov-2, and the mRNA vaccine is used for forming a micelle encapsulated preparation or freeze-drying storage.
Example 16 preparation of polyamino acid micelles comprising avian influenza virus mRNA vaccine
In a 10 ml round bottom flask, 10 mg of PLL-SSMO25-PEG2000-Biotin20 prepared in example 1 was dissolved in 300. mu.l of ethanol, and 200. mu.l of an aqueous solution containing 3 mg of avian influenza virus H7N9 subtype mRNA vaccine prepared in example 13 was rapidly added to the polyamino acid solution (water was autoclaved to ensure no active nucleolytic enzyme, pH was adjusted to 4 with hydrochloric acid). Then, the solvent was purged with nitrogen gas by a syringe to form a transparent film. 2 mL of purified water was added, and vortexed at 10 ℃ for 15 minutes in a cold room. At this volume, the concentration of PLL-SSMO25-PEG2000-Biotin20 was greater than the critical colloidal concentration (see CMC measured in example 12), and the polyamino acids and mRNA formed micellar solutions. A200 mu L sample is diluted 5 times in pure water, the solution is subjected to a dynamic laser scattering experiment (see example 12 for the method), and the hydration diameter of the micelle is measured to be 161 +/-37 nm, and the result is shown in FIG. 3. The solution was equally divided into 100 μ L samples, each containing 30 μ g of mRNA vaccine, and stored in a 4 ℃ freezer or liquid nitrogen snap-freeze.
Example 17 preparation of polyamino acid micelles comprising coronavirus mRNA vaccine
Polyamino acid micelles containing an mRNA vaccine containing the protein sequence of interest as the surface spike protein receptor binding region were prepared as described in example 16, except that 200 microliters of an aqueous mRNA vaccine solution containing 2mg of the coronavirus SARS-Cov-2 prepared in example 15 was rapidly added to the polyamino acid solution.
Example 18 preparation of a Biofunctionalized polyamino acid nanomaterial comprising an avian influenza Virus mRNA vaccine
2 ml of polyamino acid micelles containing the mRNA vaccine were prepared according to the method of example 16, and 100. mu.M streptomycin phosphate buffer was added to the sample solution until the final concentration of streptomycin was 100 nanomolar (nM). The resulting sample solution was transferred to a semipermeable membrane with a cut-off molecular weight of 1 million daltons and dialyzed in 1 liter of phosphate buffer solution of pH 6 (autoclave sterilization treatment) for 24 hours. And adding 10 mg of recombinant human serum albumin (hSA) into the dialyzed solution, freezing the obtained mixed solution, and putting the frozen mixed solution into a freeze dryer to obtain freeze-dried powder. Sealing and storing at-20 deg.C. The freeze-dried powder sample is a streptomycin functionalized poly-amino acid nano material containing mRNA vaccine.
The nano material freeze-dried powder can be re-dissolved in pure water and is used for being combined with a biotin-modified small molecule ligand and an antibody protein (such as a PD-L1 antibody, a T cell receptor antibody, an interleukin 6 receptor antibody Kevlar (sarilumab)) and the like, so that the targeted delivery of target cells and tissues is improved.
Example 19 preparation of polyamino acid-adjuvant mixture comprising influenza A mRNA vaccine
10 mg of PLL-SSMO25-PEG2000-Biotin20 prepared in example 1 and 0.5 mg of cholesterol as adjuvant, 3 mg of lecithin were co-dissolved in 300. mu.L of ethanol in a 10 ml round bottom flask, and 200. mu.L of an aqueous solution containing 3 mg of influenza A virus mRNA prepared in example 14 was rapidly added to the solution of the polyamino acid (water was autoclaved to ensure inactive nucleolytic enzyme, pH was adjusted to 4 with hydrochloric acid). Then, the solvent was purged with nitrogen gas by a syringe to form a transparent film. 2 mL of purified water was added, and vortexed at 10 ℃ for 15 minutes in a cold room. At this volume, the concentration of PLL-SSMO25-PEG2000-Biotin20 was greater than the critical colloidal concentration (see CMC measured in example 12), and the polyamino acids and mRNA formed micellar solutions. And (3) taking 200 mu L of sample, diluting the sample by 5 times in pure water, and carrying out a dynamic laser scattering experiment on the solution to obtain the hydration diameter of the micelle which is 187 +/-45 nm, wherein the result is shown in FIG. 4. The solution was equally divided into 100 μ L samples, each containing 60 μ g mRNA, and stored in a refrigerator at 4 ℃ or snap frozen in liquid nitrogen.
Example 20 preparation of polyamino acid-adjuvant mixture nanomaterial containing influenza A virus mRNA vaccine
2 mL of polyamino acid-adjuvant mixture containing mRNA vaccine was prepared according to the method of example 19, and 100. mu.M (micromolar) of streptomycin phosphate buffer was added to the sample solution until the final concentration of streptomycin was 100nM (nanomolar). Dialyzing and freeze-drying according to the method of example 18 to obtain freeze-dried powder, and storing at-20 deg.C under sealed condition. The freeze-dried powder sample is a streptomycin functionalized polyamino acid-adjuvant mixture nano material containing mRNA vaccine. When in use, the nano material is re-dissolved in pure water, and is combined with biotin-modified small molecule ligands and antibody proteins (such as PD-L1 antibody, T cell receptor antibody and the like), so that the targeted delivery to target cells and tissues is improved.
Example 21 polyamino acid nanoparticles of avian influenza virus mRNA vaccine loaded with multivalent Kjeldahl targeting antibodies
The polyamino acid nano-material lyophilized powder of the streptomycin functionalized avian influenza virus H7N9 subtype-containing mRNA vaccine prepared in example 18 was redissolved in pure water, and mixed with biotin-modified interleukin 6 receptor antibody Kevlar (sarilumab) to obtain multivalent Kevlar targeting antibody-loaded polyamino acid nanoparticles containing the mRNA vaccine.
In this example, 20% of the polyamino acid with the side chain modified with the terminal biotin-polyethylene glycol prepared in example 1 was used, and according to the average molecular weight (22.5 kDa) of poly-l-lysine and the modification ratio of 20% of biotin side chain grafting, the polyamino acid nanoparticles containing the mRNA vaccine obtained in this example are a multivalent targeted delivery system with an average of 21 biotin/streptomycin/kevlar per particle. The polyamino acid nanoparticle containing the mRNA vaccine is named as H7N9-BT21 mRNA vaccine. The change of the hydration diameter of the polyamino acid nanoparticles containing the mRNA vaccine before and after loading the kevlar targeting antibody was measured by dynamic laser scattering experiments, as shown in a in fig. 5. The results showed that the peak values of the particle sizes were 140 nm (before) and 180nm (after), respectively, i.e., the average particle size increased by 40nm upon loading the targeting antibody.
As a control experiment for a monovalent targeted mRNA vaccine, the present example prepared amphiphilic polyamino acid micellar nanoparticles comprising the avian influenza virus subtype H7N9mRNA vaccine prepared in example 13 using the polyamino acid PLL-SSDDT25-PEG2000-OMe75 of example 8. The polyamino acid side chain PLL-SSDDT25-PEG2000-OMe75 of example 8 does not contain biotin functional groups and does not have the ability to load multivalent targeting antibodies. With the coupling agent 1-ethyl-3- (-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), only the carboxyl groups of the biotin molecule can be reacted with the amine groups at the N-terminus of the backbone of the polyamino acid PLL-SSDDT25-PEG2000-OMe75 molecule. Polyamino acid nanoparticles carrying monovalent kevlar targeting antibodies containing mRNA vaccines were then prepared according to the method described above. Based on the structural characteristics of the main chain N-terminal modification, the obtained polyamino acid nanoparticles containing the mRNA vaccine are monovalent delivery systems with single biotin/streptomycin/Kjeldahl on average in single particles. The hydrated diameter of the polyamino acid nanoparticles containing the mRNA vaccine before and after loading of the kevlar targeting antibody was not changed by dynamic laser scattering experiments (130 nm, shown as B in fig. 5). It was named H7N9-BT1 mRNA vaccine. This result clearly demonstrates that the monovalent targeted H7N9-BT1 mRNA vaccine is significantly less efficient in antibody loading than the multivalent targeted vaccine, comparing a in fig. 5.
Example 22 Effect of multivalent Targeted vaccines
To verify the efficacy of the multivalent targeting vaccine, this example used the multivalent and monovalent targeting polyamino acid nanoparticles containing avian influenza virus H7N9mRNA vaccine prepared in example 21 to transfect the interleukin 6 receptor stable cell line of HEK293T, and reverse transcription-PCR quantification of the transfection efficacy was performed. The experimental procedure and results are as follows (see fig. 6).
The interleukin 6 receptor of HEK293T stably transfected cells at 37 ℃ and 5% CO2Suspension culture was carried out at 130rpm under the conditions. Diluting the cells with activity greater than 95% to 1.0 × 106cell/mL, seeded in six well plates at 1.6X 10 per well5Cells in MEM +10FBS at 37 ℃ in 5% CO2The cells were cultured in a cell incubator overnight. 2mg of H7N9-BT21 mRNA vaccine freeze-dried powder is re-dissolved in 200 muL of MEM +10FBS culture solution, 100 muL of the culture solution is added into two culture wells respectively, and the cells are continuously cultured overnight. Similarly, 2mg of H7N9-BT1 mRNA vaccine was added to each of the two wells and the cells were allowed to continue to culture overnight. The six-well plate was removed, trypsinized, and all cells were collected by centrifugation. Cells added with the H7N9-BT21 mRNA vaccine were collected as a group, designated 1. Cells added with the H7N9-BT1 mRNA vaccine were collected as a group, designated 2. The group without added vaccine is labeled 3. Reverse transcription-PCR analysis was performed on 1, 2 and 3 groups of cells, respectively, to quantify the target mRNA content of cells transfected with monovalent and multivalent targeting shoots. The Qiagen reverse transcription-PCR Kit Oligotex mRNA Mini Kit is used and the operation is carried out according to the instruction, wherein the sequence of an upstream primer is atacatcaggaagacaggagaaga, the sequence of a downstream primer is tcaatgcacctgcatcctttccaagc, and the length of the target mRNA is 2000 bp. Gel electrophoresis experimentThe results are shown in FIG. 6. The group 1 cell sample showed a significant band at the 2000 bp position. The result shows that the target mRNA in the cells added with the H7N9-BT21 mRNA vaccine is efficiently expressed, and the multivalent targeting H7N9-BT21 mRNA can efficiently transfect an HEK293T interleukin 6 receptor stable cell line. The target mRNA expression level in the cells added with the monovalent H7N9-BT1 mRNA vaccine is the same as that in the untransfected control group, and no target mRNA band can be detected. As can be seen, the interleukin 6 receptor stable cell line of H7N9-BT1 mRNA transfected HEK293T targeted univalently is far inferior to the multivalent targeted H7N9-BT21 mRNA vaccine.
Example 23 Oxidation-reduction Condition response of binary polypeptide Complex Biofunctionalized polyamino acid mRNA vaccines
10 mg of PLL-SSMO25-PEG3500-HA15-PEG3500-ALFAtag15 prepared in example 11 was dissolved in 300. mu.L of ethanol, and 200. mu.L of an aqueous mRNA sequence solution containing 3 mg of influenza A virus H1N1 prepared in example 14 was rapidly added to the binary polypeptide complex biofunctionalized polyamino acid solution (water was autoclaved to ensure inactive nuclease, pH was adjusted to 4 with hydrochloric acid). Then, the solvent was purged with nitrogen gas by a syringe to form a transparent film. 2 mL of purified water was added and vortexed in a cold chamber at 10 ℃ for 15 minutes to allow formation of a micellar solution of the PLL-SSMO25-PEG3500-HA15-PEG3500-ALFAtag15 polyamino acid and mRNA. A200 mu L sample is diluted by 5 times in pure water, and the solution is subjected to a dynamic laser scattering experiment, so that the hydration diameter of the micelle is measured to be 195 +/-45 nm, and the result is shown in FIG. 7 (solid line + black square).
To observe the oxidation-reduction condition response of the binary polypeptide composite biologically functionalized polyamino acid mRNA vaccine, another 200 μ L of the sample was weighed, 500mM Dithiothreitol (DTT) phosphate buffer was added to make the final concentration of DTT in the sample solution 5mM, and the sample was incubated at room temperature for 60 minutes. The sample was diluted to 1mL with pure water, and the solution was subjected to a dynamic laser light scattering experiment, and the hydrated diameter of the micelle in the DTT reducing environment was found to be 95 ± 65 nm, as shown in fig. 7 (dotted line + grey squares). The increased distribution width and particle size peak shift to a small particle size of 100nm, indicating that the reducing conditions cause cleavage of disulfide bonds in the polyamino acids, resulting in disruption of the intact micelle structure, which is beneficial for mRNA vaccine release.
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Sequence listing
<110> Tianjin Libo Biotechnology Ltd
<120> polyamino acid for mRNA vaccine targeted delivery, preparation method and application thereof
<141> 2021-10-01
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 73
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
cagggcagag ccatctattg cttacatttg cttctgacac aactgtgttc actagcaacc 60
tcaaacagac acc 73
<210> 2
<211> 266
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
agctcgcttt cttgctgtcc aatttctatt aaaggttcct ttgttcccta agtccaacta 60
ctaaactggg ggatattatg aagggccttg agcatctgga ttctgcctaa taaaaaacat 120
ttattttcat tgcagctcgc tttcttgctg tccaatttct attaaaggtt cctttgttcc 180
ctaagtccaa ctactaaact gggggatatt atgaagggcc ttgagcatct ggattctgcc 240
taataaaaaa catttatttt cattgc 266
<210> 3
<211> 128
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ttaataaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaaa aaaaatattc cccccccccc cccccccccc cccccccccc ctctagacaa 120
ttggaatt 128
<210> 4
<211> 104
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
agagcggccg ctttttcagc aagattaagc ccagggcaga gccatctatt gcttacattt 60
gcttctgaca caactgtgtt cactagcaac ctcaaacaga cacc 104
<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
atacatcagg aagacaggag aaga 24
<210> 6
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
tcaatgcacc tgcatccttt ccaagc 26
Claims (10)
1. A side-chain modified polyamino acid, wherein the polyamino acid comprises a backbone and a side chain; the main chain is polylysine or a copolymer formed by lysine and other amino acids; the other amino acids are selected from one or more of serine, threonine, tyrosine, arginine, histidine, glycine, leucine, isoleucine, valine, phenylalanine, tryptophan, proline, asparagine and glutamine;
at least part of the side chains respectively contain a group A and a group G, wherein the group A is-L3-S-S-C4-25Aliphatic hydrocarbonsBase, L3Is C1-10An aliphatic alkylene radical, the group G being selected from the group G1 and/or the group G2, wherein the group G1 is terminated by a C1-10The polyethylene glycol group of alkoxy, the group G2 is a polyethylene glycol group with a biological functional group connected with the end group;
the group a and the group G are linked to the amino acids in the backbone via a linking group Y.
2. The polyamino acid of claim 1, wherein the group G1 is-L1-PEG-L2-Z1-D, wherein PEG is a polyethylene glycol segment and D is C1-10Alkoxy radical, Z1Is a linking group, L1、L2Is a direct bond or a spacer group;
the group G2 is-L1-PEG-L2-Z2-E, wherein PEG is a polyethylene glycol segment, E is a biofunctional group, Z2Is a linking group, L1、L2Is a direct bond or a spacer group.
3. The polyamino acid of claim 2, wherein L1、L2Is a direct bond or C1-10An alkyl group;
the linking group Z1、Z2Comprises the following groups:
-CO-NH-、-CO-O-、-O-、-O-CH2-CO-、-NH-、-N=CR1-、-N-CHR1-、-NH-CH2-CO-、-S-S-、-S-CO-、-S-CH2-CO-orAny one of a connecting group obtained by click reaction of azido and alkynyl and a connecting group obtained by click reaction of tetrazine and double bond;
the biological functional group is a bonder capable of being combined with protein, polypeptide and amino acid, and comprises a artificially synthesized bonder or natural biological molecules.
4. The polyamino acid of any one of claims 1 to 3, wherein the side chain modified polyamino acid may be one of the following: polyamino acids comprising group a and group G1, polyamino acids comprising group a and group G2, polyamino acids comprising group a, group G1 and group G2;
in the polyamino acid, the mole percentage of the number of side chains containing a group G1 and/or a group G2 to the total amount of all side chains is 2-98%, the mole percentage of the number of side chains containing a group A to the total amount of all side chains is 2-98%, and the mole percentage of the sum of the number of side chains containing a group A and the number of side chains containing a group G1 and/or a group G2 to the total amount of all side chains is 5-100%.
5. A side chain modified polyamino acid is prepared by the following preparation method:
the polyamino acid with side chain having active group is connected with one end of C1-10Polyethylene glycol with reactive group x1 connected to the other end of alkoxy group and/or polyethylene glycol with biological functional group connected to one end and reactive group x2 connected to the other end, and C with reactive group x3 connected to the other end and activated disulfide bond1-10Reacting aliphatic hydrocarbon; wherein the reactive groups x1, x2 and x3 react with the active groups on the side chain of the polyamino acid, such that the end group is provided with C1-10Polyethylene glycol of alkoxy and/or biological functional group and aliphatic hydrocarbon containing activated disulfide bond group are connected to the side chain of polyamino acid; then the product is mixed with C4-25And (3) reacting aliphatic hydrocarbon mercaptan to prepare the side chain modified polyamino acid.
6. The polyamino acid of claim 5, wherein the activated disulfide bond is-S-S-pyridyl.
7. A method for producing the side-chain-modified polyamino acid according to any one of claims 1 to 6, comprising the steps of:
the polyamino acid with side chain having active group is connected with one end of C1-10Polyethylene glycol with reactive group x1 connected to the other end of alkoxyAnd/or polyethylene glycol with a biological functional group connected to one end and a reactive group x2 connected to the other end, and C with a reactive group x3 connected to one end and an activated disulfide bond connected to the other end1-10Reacting aliphatic hydrocarbon; wherein the reactive groups x1, x2 and x3 react with the active groups on the side chain of the polyamino acid, such that the end group is provided with C1-10Polyethylene glycol of alkoxy and/or biological functional group and aliphatic hydrocarbon with activated disulfide bond at the end group are connected to the side chain of polyamino acid; then the product is mixed with C4-25And (3) reacting aliphatic hydrocarbon mercaptan to prepare the side chain modified polyamino acid.
8. A micelle comprising the side chain-modified polyamino acid of any one of claims 1 to 6.
9. A delivery system comprising the micelle of claim 8 and a nucleic acid molecule, the nucleic acid molecule being located within the micelle.
10. The delivery system of claim 9, wherein the nucleic acid molecule is an RNA vaccine, an RNA drug, a DNA vaccine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111168338.4A CN113788951A (en) | 2021-10-08 | 2021-10-08 | Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111168338.4A CN113788951A (en) | 2021-10-08 | 2021-10-08 | Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113788951A true CN113788951A (en) | 2021-12-14 |
Family
ID=79184572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111168338.4A Pending CN113788951A (en) | 2021-10-08 | 2021-10-08 | Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113788951A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023231047A1 (en) * | 2022-05-30 | 2023-12-07 | 浙江大学 | Nanoparticle nucleic acid vector comprising hyperbranched polylysine, and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010025568A (en) * | 2008-07-15 | 2010-02-04 | Hitachi High-Technologies Corp | Single probe molecule element and single probe molecule-immobilized metal particle |
US20130253135A1 (en) * | 2010-11-19 | 2013-09-26 | Stephanie E. Barrett | Poly(amide) polymers for the delivery of oligonucleotides |
CN104497097A (en) * | 2014-06-18 | 2015-04-08 | 深圳市第二人民医院 | Protein or polypeptide-polymer grafted copolymer with reduction responsiveness, synthesis method and protein or polypeptide drug thereof |
CN106389388A (en) * | 2016-11-10 | 2017-02-15 | 苏州大学 | PH redox double-sensitive PAMAM targeting nano drug delivery carrier and preparation method thereof |
CN110177569A (en) * | 2017-03-30 | 2019-08-27 | 江苏恒瑞医药股份有限公司 | The preparation method of antibody drug conjugates |
CN112266483A (en) * | 2020-12-22 | 2021-01-26 | 天津力博生物科技有限公司 | Side chain modified polyamino acid and preparation method and application thereof |
-
2021
- 2021-10-08 CN CN202111168338.4A patent/CN113788951A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010025568A (en) * | 2008-07-15 | 2010-02-04 | Hitachi High-Technologies Corp | Single probe molecule element and single probe molecule-immobilized metal particle |
US20130253135A1 (en) * | 2010-11-19 | 2013-09-26 | Stephanie E. Barrett | Poly(amide) polymers for the delivery of oligonucleotides |
CN104497097A (en) * | 2014-06-18 | 2015-04-08 | 深圳市第二人民医院 | Protein or polypeptide-polymer grafted copolymer with reduction responsiveness, synthesis method and protein or polypeptide drug thereof |
CN106389388A (en) * | 2016-11-10 | 2017-02-15 | 苏州大学 | PH redox double-sensitive PAMAM targeting nano drug delivery carrier and preparation method thereof |
CN110177569A (en) * | 2017-03-30 | 2019-08-27 | 江苏恒瑞医药股份有限公司 | The preparation method of antibody drug conjugates |
CN112266483A (en) * | 2020-12-22 | 2021-01-26 | 天津力博生物科技有限公司 | Side chain modified polyamino acid and preparation method and application thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023231047A1 (en) * | 2022-05-30 | 2023-12-07 | 浙江大学 | Nanoparticle nucleic acid vector comprising hyperbranched polylysine, and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112266483A (en) | Side chain modified polyamino acid and preparation method and application thereof | |
Schwarz et al. | Biomedical and catalytic opportunities of virus-like particles in nanotechnology | |
Meyer et al. | Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA− polymer conjugate | |
Gupta et al. | Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold | |
Lacerda et al. | Cell-penetrating CNTs for delivery of therapeutics | |
Schaffert et al. | Poly (I: C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier | |
EP2884965B1 (en) | Internal structured self assembling liposomes | |
US20110312877A1 (en) | Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use | |
US20190382790A1 (en) | Perfluorocarbylated compounds for the non-viral transfer of nucleic acids | |
WO2007086923A2 (en) | Controlled and sustained gene transfer mediated by thiol-modified polymers | |
CN117098558A (en) | Polyoxazoline-lipid conjugates, lipid nanoparticles comprising same, and pharmaceutical compositions | |
US20220233459A1 (en) | Analysis of materials for tissue delivery | |
HU227264B1 (en) | Method for preparing functionalised polyalkylenimines, composition containing same and uses thereof | |
WO2020241819A1 (en) | Complex, medicine, therapeutic agent for cancer, kit and conjugate | |
CN113788951A (en) | Polyamino acid for mRNA vaccine targeted delivery and preparation method and application thereof | |
van Rossenberg et al. | Stable polyplexes based on arginine-containing oligopeptides for in vivo gene delivery | |
JP2003503569A (en) | Copolymer for transporting nucleic acids to cells | |
JP2011184391A (en) | Nucleic acid introducing agent made of organic nanotube | |
CN116271078A (en) | Synthesis method of targeted drug nCoVshRNA.2ACE2 | |
JP2024512505A (en) | Dendritic peptide-conjugated polymers for efficient intracellular delivery of nucleic acids to immune cells | |
US7368240B2 (en) | Microscope system and methods for intracellular studies | |
US9198974B2 (en) | Decorated macromolecular scaffolds | |
CN116254256A (en) | Synthesis method of chemical drug nCoVshRNA.2RBD | |
CN115678916A (en) | Lipopeptide carrier for efficiently delivering nucleic acid drugs and preparation method and application thereof | |
EP4296274A1 (en) | Peptides for intracellular delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211214 |